文献速递药物相互作用治疗药物监测与药物基因组学

局部晚期直肠癌患者瑞戈非尼与卡培他滨群体药代动力学分析

Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP).
PubMed 文献 · Br J Clin Pharmacol · 2022-07-23

SAKK 41/16 RECAP试验评估瑞戈非尼联合卡培他滨及放疗治疗局部晚期直肠癌,采用群体药代动力学模型分析药物暴露与相互作用。研究发现瑞戈非尼累积暴露使卡培他滨表观清除率中位降低45.6%,提示两者存在显著药物相互作用。

要点

  • 瑞戈非尼累积AUC与卡培他滨清除率呈负相关,中位降低45.6%。
  • 卡培他滨表观清除率为286 L/h(RSE 14.9%,IIV 40.1%)。
  • 瑞戈非尼表观清除率为1.94 L/h(RSE 12.1%,IIV 38.1%)。

核心结论

  • 瑞戈非尼暴露增加会显著降低卡培他滨的清除率,提示两者存在潜在药物相互作用。

研究设计与样本

  • 基于SAKK 41/16试验,患者接受瑞戈非尼40/80/120 mg每日一次联合卡培他滨825 mg/m2每日两次及局部放疗。
  • 构建卡培他滨及其代谢物与瑞戈非尼及其代谢物的群体药代动力学模型,评估药物相互作用。

主要发现

  • 卡培他滨、瑞戈非尼及其代谢物血药浓度分别用一室和二室模型描述。
  • 卡培他滨表观清除率为286 L/h(RSE 14.9%,IIV 40.1%)。
  • 瑞戈非尼累积AUC作为指数协变量使卡培他滨清除率中位降低45.6%(估计值-4.10×10^-4,RSE 17.8%)。
  • 瑞戈非尼表观清除率为1.94 L/h(RSE 12.1%,IIV 38.1%)。
  • 模拟分析显示卡培他滨清除率与瑞戈非尼暴露呈显著负相关。

临床怎么用

  • 联合用药时应关注瑞戈非尼对卡培他滨暴露的影响,必要时进行治疗药物监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Locally advanced rectal cancer (LARC) is an area of unmet medical need with one third of patients dying from their disease. With response to neoadjuvant chemo-radiotherapy being a major prognostic factor, trial SAKK 41/16 assessed potential benefits of adding regorafenib to capecitabine-amplified neoadjuvant radiotherapy in LARC patients. METHODS: Patients received regorafenib at three dose levels (40/80/120 mg once daily) combined with capecitabine 825 mg/m2 bidaily and local radiotherapy. We developed population pharmacokinetic models from plasma concentrations of capecitabine and its metabolites 5'-deoxy-5-fluorocytidine and 5'-deoxy-5-fluorouridine as well as regorafenib and its metabolites M-2 and M-5 as implemented into SAKK 41/16 to assess potential drug-drug interactions (DDI). After establishing parent-metabolite base models, drug exposure parameters were tested as covariates within the respective models to investigate for potential DDI. Simulation analyses were conducted to quantify their impact. RESULTS: Plasma concentrations of capecitabine, regorafenib and metabolites were characterized by one and two compartment models and absorption was described by parallel first- and zero-order processes and transit compartments, respectively. Apparent capecitabine clearance was 286 L/h (relative standard error [RSE] 14.9%, interindividual variability [IIV] 40.1%) and was reduced by regorafenib cumulative area under the plasma concentration curve (median reduction of 45.6%) as exponential covariate (estimate -4.10 × 10-4 , RSE 17.8%). Apparent regorafenib clearance was 1.94 L/h (RSE 12.1%, IIV 38.1%). Simulation analyses revealed significantly negative associations between capecitabine clearance and regorafenib exposure. CONCLUSIONS: This work informs the clinical development of regorafenib and capecitabine combination treatment and underlines the importance of studying potential DDI with new anticancer drug combinations.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Schmulenson E, Bovet C, Theurillat R, et al. Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP). Br J Clin Pharmacol. 2022. PMID: 35831229. doi:10.1111/bcp.15461

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。